Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.

Article English OPEN
ElNaggar, Adam C.; Hays, John L.; Chen, James L.;
(2016)
  • Publisher: Public Library of Science (PLoS)
  • Journal: PLoS ONE, volume 11, issue 6 (issn: 1932-6203, eissn: 1932-6203)
  • Publisher copyright policies & self-archiving
  • Related identifiers: pmc: PMC4905654, doi: 10.1371/journal.pone.0156985
  • Subject: Cancer Treatment | Research Article | Ewing Sarcoma | Anatomy | Research Design | Case Series | Cardiovascular Physiology | Oncology | Leiomyosarcoma | Biological Tissue | Soft Tissues | Endocrine Physiology | Cancers and Neoplasms | Sarcomas | Biology and Life Sciences | Growth Factors | Angiogenesis | Developmental Biology | Research and Analysis Methods | Clinical Research Design | Physiology | Medicine | Q | R | Science | Medicine and Health Sciences | Endocrinology

Background Patients with metastatic sarcoma who progress on vascular endothelial growth factor receptor inhibitors (VEGFRi) have limited treatment options. Upregulation of the mTOR pathway has been demonstrated to be a means of resistance to targeted VEGFRi in metastati... View more
Share - Bookmark